Chemomab Therapeutics Ltd.
CMMB · XNASCIK 1534248fmd_16FGYYNX79X5EF6908DE5ZX7TJManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Dec 31, 2025, 28 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | – | – | – | – | – | 3 | 5 | 4 | 2 | 2 |
| Research and development | 2 | 6 | 8 | 13 | 5 | 6 | 17 | 18 | 11 | 6 |
| Total operating expenses | – | – | 13 | 23 | 6 | 12 | 29 | 25 | 15 | 10 |
| Operating income | (5) | (9) | (13) | – | – | – | – | – | (103) | (112) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | – | – | – | – | – |
| Other non-operating income (expense) | – | – | – | – | – | (0) | 0 | 1 | 1 | 1 |
| Income before taxes | (5) | (9) | 13 | 27 | 6 | (12) | (28) | (24) | (14) | (9) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | (1) | 0 | 0 | 0 |
| Net income from continuing operations | (5) | (10) | 13 | 27 | 6 | (12) | (28) | (24) | (14) | (9) |
| Net income | (5) | (10) | (14) | (27) | (6) | (12) | (28) | (24) | (14) | (9) |
| Net income to common shareholders | 5 | 10 | 13 | – | – | – | – | – | – | – |